VDR agonists increase sensitivity of MCF-7 and BT-474 breast cancer cells to 5 FU

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: The study aimed to test the potential for increasing the antiproliferative activity of 5-fluorouracil against breast cancer cells of various molecular subtypes by Vitamin D receptor (VDR) agonists, calcitriol and tacalcitol, used at a low concentration of 10 nM. Materials and Methods: Calcitriol and tacalcitol were used to increase the antiproliferative effect of 5-fluorouracil against the following human breast cancer cell lines: MCF- 7, T47D, BT-474 (luminal); JIMT-1, SKBR-3 (HER2- enriched); MDA-MB-231 (triple-negative/basal-B), and nonmalignant MCF-10A breast epithelial cells. Results: Both calcitriol and tacalcitol significantly increased the sensitivity of MCF-7 and BT-474 cells to the antiproliferative effect of 5-fluorouracil, while no increase in the sensitivity of MDAMB- 231 cells to 5-fluorouracil treatment was observed. Conclusion: The VDR agonist used at the relatively low concentration of 10 nM may increase the sensitivity of breast cancer cells, at least of the luminal subtype, to the antiproliferative effect of 5-fluorouracil.

Cite

CITATION STYLE

APA

Klopotowska, D., & Matuszyk, J. (2020). VDR agonists increase sensitivity of MCF-7 and BT-474 breast cancer cells to 5 FU. Anticancer Research, 40(2), 837–840. https://doi.org/10.21873/anticanres.14015

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free